As co-treatment with a PIM kinase inhibitor prevented ruxolitinib resistance in vitro, our data supports the rational of using PIM inhibitors as a combination treatment with JAK inhibitors in JAK mutated MPN. This evidence concerns the gene PIM1 and myeloproliferative disorder.